AMPH vs STE: fair value comparison
Amphastar Pharmaceuticals, Inc. and STERIS plc · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STE currently sits closer to the top of our ranking by discount to fair value. STE carries the stronger quality grade.
| AMPH | STE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.87 | $214.40 |
| 12-month range | $16.87–$29.40 | $199.40–$268.65 |
| Rank by discount to fair value | #27 of 108 Healthcare | #25 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: AMPH fair value analysis · STE fair value analysis